| 1 |
|
A PAR domain transcription factor is involved in the expression from a hematopoietic-specific promoter for the human LMO2 gene/
|
Crable, S. C
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2 |
|
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia/
|
Fiedler, W
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 3 |
|
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911/
|
Press, O. W
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 4 |
|
A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans/
|
Li, Z
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 5 |
|
A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia/
|
Bekri, S
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 6 |
|
p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation/
|
Canitrot, Y
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 7 |
|
P2X1: definitely not an ADP receptor/
|
Rosa, J.-P
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 8 |
|
Patient selection and goals/
|
Vesole, D. H
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 9 |
|
Pax5 determines B- versus T-cell fate and does not block early myeloid-lineage development/
|
Cotta, C. V
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 10 |
|
PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A/
|
Moon, E.-Y
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 11 |
|
PECAM-1/CD31 provides survival signals to suppress apoptosis/
|
Jackson, D. E
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 12 |
|
PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosis/
|
Gao, C
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 13 |
|
PECAM-1 negatively regulates GPIb/V/IX signaling in murine platelets/
|
Rathore, V
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 14 |
|
Penetrance in hereditary hemochromatosis/
|
McCune, A
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 15 |
|
Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia/
|
Shen, C.-R
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 16 |
|
Peptidoglycan recognition and neutrophil function/
|
Weiss, J
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 17 |
|
Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator/
|
Ramezani, A
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 18 |
|
Peripheral smear from a patient with beta thalassemia-HbE disease/
|
Schrier, S
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 19 |
|
Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients/
|
Bekkenk, M. W
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 20 |
|
Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice/
|
Lee, T.-H
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|